Today’s biologic drugs are providing breakthrough treatment options for many of the world’s most challenging diseases and chronic conditions.

As a supplier for the largest biopharmaceutical manufacturers in the world, Avantor® is trusted to provide the products, services, solutions and expertise necessary to quickly and confidently move through research and production. From the small-scale bench, to pilot plant and full commercial manufacturing, we enable our customers to reach the market with new treatments for patients, faster and safer.

We provide a unique combination of industry expertise with the broadest portfolio of products and materials engineered and manufactured to satisfy the highest quality standards and regulatory requirements for your final product—whether it is a vaccine, monoclonal antibody, recombinant protein, cell therapy, gene therapy or small molecule treatment.

Focused on the success of your applications and processes


Avantor is a strategic partner with proven insight into the biopharmaceutical industry’s workflows, needs and challenges. Serving your needs from discovery to commercial launch, our portfolio of industry-leading production chemicals, single-use solutions and sera are backed by our deep commitment to quality and innovation.

Starting with raw material procurement and ranging to cGMP manufacturing at multiple scales, handling and distribution, we emphasize all aspects of quality in our own processes. Our quality systems are proven and have been audited by biopharmaceutical manufacturers and regulatory bodies worldwide. We keep you informed of pertinent changes that could impact your processes to help you achieve faster compliance and clear the path for regulatory approval.

Our channel, VWR®, part of Avantor, provides an integrated purchasing experience that is optimized for the way you do business, with access to an even broader selection of products to use in upstream and downstream processes as well as final fill formulations.

Opportunities and challenges in cell and gene therapy development

Q&A interview with Ger Brophy, Executive Vice President for Biopharma Production at Avantor